Pseudocirrhosis due to palbociclib treatment in patient with breast cancer and liver metastasis

For patients with breast cancer, obtaining tissue samples from liver lesion becomes more and more important for both differential diagnosis and subsequent treatment. However, the procedure is not considered as mandatory routine and is not frequently performed. We here reported about a patient with breast cancer history and a solitary liver metastasis that was clinically diagnosed by both magnetic resonance imaging (MRI) and position emission tomography - computed tomography (PET-CT). However, pathologic diagnosis after partial hepatectomy (between sections VII and VIII) revealed multifocal granulomas. The case further addresses the importance of core needle biopsy, or surgical biopsy, for obtainment of a histological diagnosis, especially in the presence of a solitary lesion, even when the lesion has a typical medical imaging supporting metastasis, and uptake of radioactive 18F-fluorodeoxyglucose (18F-FDG) by PET-CT.

Download Full-text

Abstract PS4-02: The immune microenvironment of liver metastasis as a guide for immunotherapeutic potential in breast cancer

10.1158/1538-7445.sabcs20-ps4-02 ◽

2021 ◽

Author(s):

Sofi Castanon ◽

Daniel Flores ◽

Joanne Xiu ◽

Paula R. Pohlmann ◽

Foluso Ademuyiwa ◽

...

Keyword(s):

Breast Cancer ◽

Liver Metastasis ◽

Immune Microenvironment

Download Full-text

167P TRIP13 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse

Annals of Oncology ◽

10.1016/j.annonc.2020.03.267 ◽

2020 ◽

Vol 31 ◽

pp. S76

Author(s):

Z. Du ◽

Y. Wang ◽

Q. Lv

Keyword(s):

Breast Cancer ◽

Liver Metastasis ◽

Prognostic Indicator ◽

Metastatic Relapse ◽

Poor Prognostic Indicator

Download Full-text

BRECLIM - a randomized clinical trial investigating local treatment for breast cancer liver metastasis

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2019.11.457 ◽

2020 ◽

Vol 46 (2) ◽

pp. e14

Author(s):

Oskar Hemmingsson ◽

Malin Sund ◽

Helena Taflin ◽

Marcus Sundén ◽

Anne Andersson

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Liver Metastasis ◽

Randomized Clinical Trial ◽

Local Treatment ◽

Breast Cancer Liver Metastasis

Download Full-text

Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports

Case Reports in Oncology ◽

10.1159/000493848 ◽

2018 ◽

Vol 11 (3) ◽

pp. 699-704 ◽

Cited By ~ 3

Author(s):

Takatsugu Ogata ◽

Yuichiro Kikawa ◽

Misato Ogata ◽

Hironaga Satake ◽

Yukimasa Hatachi ◽

...

Keyword(s):

Breast Cancer ◽

Computed Tomography ◽

Liver Metastasis ◽

Liver Failure ◽

Acute Liver Failure ◽

Hepatic Failure ◽

Poor Prognosis ◽

Alcoholic Hepatitis ◽

Case Reports ◽

History Of

Diffuse liver metastasis is a rare pattern of liver metastasis that is associated with hepatic failure and poor prognosis. We experienced 2 cases of acute liver failure due to diffuse metastasis that could not be detected using computed tomography. In case 1, it was difficult to differentiate diffuse metastasis from alcoholic hepatitis. In case 2, it was difficult to diagnose diffuse liver metastasis because the patient had no history of malignancy. When liver enzyme levels are elevated, it is necessary to consider liver metastasis as a potential cause, regardless of computed tomography findings.

Download Full-text

High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

International Journal of Breast Cancer ◽

10.1155/2020/7156574 ◽

2020 ◽

Vol 2020 ◽

pp. 1-7

Author(s):

Atsushi Fushimi ◽

Isao Tabei ◽

Azusa Fuke ◽

Tomoyoshi Okamoto ◽

Hiroshi Takeyama

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Liver Metastasis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Postmenopausal Breast Cancer ◽

Rank Test ◽

High Dose ◽

Secondary Resistance ◽

Hormone Receptor Positive

There are currently no established second- and later-line therapies for postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer. We examined the efficacy of high-dose toremifene (HD-TOR) for this patient group and whether aromatase inhibitor (AI) resistance influences HD-TOR treatment outcome. This retrospective analysis investigated the outcomes of 19 women with postmenopausal hormone-sensitive recurrent or metastatic breast cancer who received HD-TOR, defined as 120 mg daily from 2012 to 2016. The median follow-up duration was 9.67 months. The overall response rate (ORR) and clinical benefit rate (CBR) were compared between various clinical subgroups, including patients exhibiting primary or secondary AI resistance as defined by the timing of recurrence or progression. Time to treatment failure (TTF) was estimated by the Kaplan–Meier method and compared between subgroups by the log-rank test. The overall ORR was 21.1%, and the CBR was 31.6%. CBR was significantly higher for patients without liver metastasis (50% vs. 0%, p=0.044). Nine cases exhibited primary and eight cases secondary AI resistance. Both ORR and CBR were higher in patients with secondary AI resistance (25% vs. 0%, p=0.087; 38% vs. 11%, p=0.29). The median TTF was 6.2 months in the entire AI-resistant group (n=17) and was longer in the secondary resistance subgroup than in the primary resistance subgroup (8.40 vs. 4.87 months; log-rank: p=0.159). High-dose TOR appears to be most effective for postmenopausal breast cancer cases with secondary resistance to AIs, cases without prior AI treatment, and cases without liver metastasis. The detailed mechanisms of AI resistance and the clinical features of responsive cases need to be further clarified to identify the best candidates for HD-TOR.

Download Full-text

Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma

Scientific Reports ◽

10.1038/s41598-019-52841-y ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 1

Author(s):

Petros Tsantoulis ◽

Mauro Delorenzi ◽

Ivan Bièche ◽

Sophie Vacher ◽

Pascale Mariani ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Colorectal Cancer ◽

Liver Metastasis ◽

Uveal Melanoma ◽

Meta Analysis ◽

Prognostic Score ◽

Penalized Regression ◽

Breast Cancer Patients ◽

Public Data

AbstractPredicting the risk of liver metastasis can have important prognostic and therapeutic implications, given the availability of liver-directed therapy. Uveal melanoma has a striking predisposition for liver metastasis despite the absence of anatomical proximity. Understanding its biology may uncover factors promoting liver metastasis in other malignancies. We quantified gene expression by RNAseq in 76 uveal melanomas and combined with public data in a meta-analysis of 196 patients. The meta-analysis of uveal melanoma gene expression identified 63 genes which remained prognostic after adjustment for chromosome 3 status. Two genes, PTP4A3 and JPH1, were selected by L1-penalized regression and combined in a prognostic score. The score predicted liver-specific relapse in a public pan-cancer dataset and in two public colorectal cancer datasets. The score varied between colorectal consensus molecular subtypes (CMS), as did the risk of liver relapse, which was lowest in CMS1. Additional prospective validation was done by real-time PCR in 463 breast cancer patients. The score was significantly correlated with liver relapse in hormone receptor positive tumors. In conclusion, the expression of PTP4A3 and JPH1 correlates with risk of liver metastasis in colorectal cancer and breast cancer. The underlying biological mechanism is an interesting area for further research.

Download Full-text